Genentech chosen as a 2016 FOYA category winner
Genentech has won the Process Innovation category for its large-scale, Cell Culture Biologics Drug Substance Plant 2 (CCP2) located in Vacaville, CA.
Genentech (a member of the Roche Group) won the Process Innovation category for its large-scale, Cell Culture Biologics Drug Substance Plant 2 (CCP2) located in Vacaville, CA. This project focused upon an upgrade to the original CCP2 facility, put into an idle but “keep warm” status in 2010, combined with a fast track Return to Service project. The Return to Service project, and its fast track timing, was driven by a need to support product supply to patients of two significant oncology products whose market demand has tripled in recent years.
The facility itself is large scale including 450,000 sq ft of manufacturing and support space. The manufacturing process utilizes some of the largest scale cell culture drug substance production equipment in the industry, including 8 x 25,000-L bioreactors, 1.8-m diameter chromatography columns, and 7 CIP skids serving upstream and downstream areas.
Innovative approaches were used throughout the manufacturing process and key process support areas, to convert the original design basis and installation to Genentech’s newest process technology, global standards of best in class compliance standards, and sustainability goals while maintaining the shortest fast track schedule possible.
Process innovations include high titre yields at the largest bioreactor scale used in the industry, and the complete conversion of downstream processing and all fluid handling systems to support the recovery of this higher titre output compared to the original installation’s lower titre design criteria. Equipment redundancies and labor sharing were balanced between CCP2 and CCP1, and the facility and process automation was significantly expanded in scope to reduce product production cost.
Revamping the existing CCP2 Facility to support new process technology in lieu of building new resulted in significant savings in capital ($50M). The project was completed 2 months ahead of schedule, ensuring patient product supply.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance